India strategic launchpad for next wave of obesity care

[ad_1] India is set to emerge as the next hub for semaglutide active pharmaceutical ingredient (API) after China, with top drugmakers building significant capacity to tap the booming global market for obesity and diabetes drugs, market research firm IQVIA said in a report.Companies including Aurobindo, Dr Reddy’s, Lupin, Alembic and Biocon are investing in kilo-scale…

Read More